<DOC>
	<DOCNO>NCT02001571</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics ( study body drug ) 1000 mg oral dose abiraterone acetate major metabolite ( ) mild moderate hepatic impairment match control Participants normal hepatic function .</brief_summary>
	<brief_title>A Study Assess Effect Abiraterone Acetate Male Participants With Mild Moderate Hepatic Impairment Compared Matched Control Participants With Normal Hepatic Function</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) pharmacokinetics safety study abiraterone acetate administer four 250 mg tablet ( 1000 mg ) 3 cohort ( group ) Cohort 1 ( Mild Hepatic Impairment ) , Cohort 2 ( Moderate Hepatic Impairment ) Cohort 3 ( Normal Hepatic Function ) . There approximately 8 Participants per cohort ( total approximately 24 Participants study ) . The cohort dose sequentially activity consist Screening , Study Follow-up period , total approximately 36 day . Possible Participants screen assess eligibility enter study within 14 day prior study Day 1 . Participants confine Clinical Research Center ( CRC ) time Check-in Day -1 discharge Day 5 . Participants return CRC Days 8 15 follow-up call visit Day 22 . A review clinical laboratory data Day 8 evaluation cohort do Medical Monitor Principal Investigator ( PI ) prior proceed dose cohort , indicate . Safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Non smoker light smoker willing limit smoking period confinement 4 cigarette per day Body Mass Index 1835 kg/m2 Negative test breathalyzer alcohol drug abuse HIV antibody test Screening Agrees protocoldefined use effective contraception Participants Mild Moderate Hepatic Impairment Must mild moderate hepatic impairment On stable dose medication and/or treatment regimen least 2 week dose well study Clinical laboratory evaluation within reference range test laboratory Participants normal hepatic function clinically significant finding medical history , physical examination , Laboratory value within protocol define parameter Any investigational study drug trial within 5 halflives investigational study drug 30 day prior dose Abiraterone acetate , whichever long Inability swallow four ( 4 ) 250 mg abiraterone acetate tablet History current clinically significant medical illness would potentially alter absorption and/or excretion orally administer drug History presence clinically significant abnormal ECG Donation blood significant loss blood within 56 day prior Day 1 plan donation blood plasma Screening 30 day Day 1 Use prescription medications/products OTC , nonprescription unrelated exist allowable stable medical condition within 5 halflives product 7 day prior dose abiraterone acetate , whichever longer Clinically significant renal laboratory finding Participants Mild Moderate Hepatic Impairment exclude significant medical history hepatic impairment may affect interpretation data otherwise contraindicate participation study Acute exacerbate hepatitis , fluctuate rapidly deteriorate hepatic function indicate widely vary worsen clinical and/or laboratory sign hepatic impairment within 2 week Autoimmune liver disease ; Esophageal variceal bleed within 6 month prior Screening , unless successfully treat banding , Gastric varices Spontaneous bacterial peritonitis within 3 month prior Screening Portosystemic shunt , Organ transplant , Wilson 's disease , Cholestatic liver disease ( e g , primary biliary cirrhosis primary sclerosing cholangitis ) Clinically significant laboratory finding except related hepatic impairment Control Participants Normal Hepatic Function Any significant laboratory result , include specifically Positive Hepatitis B C , Hemoglobin &lt; 12 0 g/dL LFTs outside normal limit</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>